生产企业：BioMarin Pharmaceutical
BMN-333 is a Voxzogo follow-on, a longer-acting CNP (C-type natriuretic peptide) being developed by BioMarin Pharmaceutical for multiple growth disorders such as achondroplasia.
BMN-333 is a Voxzogo follow-on, a longer-acting CNP (C-type natriuretic peptide) being developed by BioMarin Pharmaceutical for multiple growth disorders such as achondroplasia.
Longer-acting CNP (C-type natriuretic peptide) analog; developed as a follow-on to Voxzogo (vosoritide)
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
